N/A
Completed N=70
Positive Psychology Intervention In HSCT
Hematologic Malignancy · Hematopoietic/Lymphoid Cancer · Blood Cancer
Source: ClinicalTrials.gov NCT05147311 ↗
Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcomePrimary: Feasibility Rate — 31 Participants
Summary
The main purpose of this research study is to determine if a positive psychology-based program in people who have received a stem cell transplant for blood cancer treatment is feasible and acceptable, and can help improve positive feelings, mood, quality of life, overall wellbeing and health.
The Positive psychology for Allogenic Transplantation of Hematopoietic stem cell intervention (PATH), a novel 9-week phone-administered Positive psychological intervention (PPI).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility Rate |
31 | — |
| SECONDARY Acceptability Rate |
7.40; 8.23 | — |
| SECONDARY Mean Quality of Life Scores |
99.84; 103.72; 107.02; 113.82; 111.63; 109.06 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients (≥ 18 years) with hematologic malignancies who have received allogeneic HSCT at Dana Farber Cancer Institute who are approaching 100-day post-transplant milestone.
- Ability to speak, read and write English.
- Access to a telephone.
Exclusion Criteria
- Cognitive deficits impeding a study participant's ability to provide informed consent or participate adequately in the study procedures assessed via a commonly used 6-item cognitive assessment with the Brief Interview for Mental Status (BIMS).
- Medical conditions precluding interviews.
- Patients undergoing HSCT for benign hematologic conditions.
- Patients undergoing outpatient HSCT.
- Patients with psychiatric or cognitive conditions which the treating clinicians believes prohibits compliance with study procedures.
- Patients who are unable to verbally consent or are not yet adults (including infants, children, teenagers), pregnant women, or prisoners.
Data sourced from ClinicalTrials.gov (NCT05147311). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.